Can-Fite BioPharma vs Scienture
CANF and SCNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CANF and SCNX compare
Scienture scores higher on the StockData Score (3 against 1 for Can-Fite BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CANF | SCNX |
|---|---|---|
| Size and price | ||
| Market cap | – | $123M |
| Share price | $1.56 | $2.99 |
| Change, 1 year | −79.0% | −82.2% |
| Change, 5 years | −99.4% | −99.8% |
| Beta (5Y) | 1.44 | 1.07 |
| Employees | 5 | 8 |
| StockData Score | ||
| Total score | 1 | 3 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 1.9× |
| Growth | ||
| Revenue growth (TTM) | −39.9% | – |
| Revenue growth, 5Y average | −11.9% (better) | −52.1% |
| Profitability | ||
| Operating margin | −2457% | – |
| Net margin | −2427% | – |
| FCF margin | −2210% | – |
| Return on equity | −217% | −53.5% (better) |
| Return on invested capital | – | −47.3% |
| Financial health | ||
| Interest coverage | −35.0× | −13.1× (better) |
| Current ratio | 3.60 (better) | 3.04 |
| Altman Z-score | – | 0.31 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 1.9% | – |
| Held by insiders | 0.00% | 16.6% |
| Short interest, % of float | – | 0.34% |
Go deeper
- CANF stock overview
- CANF income statement
- CANF valuation and score
- SCNX stock overview
- SCNX income statement
- SCNX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.